These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35799757)

  • 1. Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression.
    Shao S; Sun B; Sun H
    Pak J Med Sci; 2022; 38(5):1389-1394. PubMed ID: 35799757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial.
    Shin C; Jeon SW; Lee SH; Pae CU; Hong N; Lim HK; Patkar AA; Masand PS; An H; Han C
    Clin Psychopharmacol Neurosci; 2023 Feb; 21(1):135-146. PubMed ID: 36700320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study.
    Lee SH; Jeon SW; Shin C; Pae CU; Patkar AA; Masand PS; An H; Han C
    Psychiatry Investig; 2022 Apr; 19(4):268-280. PubMed ID: 35500900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study.
    De Filippis S; Pugliese A; Christensen MC; Rosso G; Di Nicola M; Simonsen K; Ren H
    Neuropsychiatr Dis Treat; 2022; 18():1665-1677. PubMed ID: 35971416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.
    Wang G; You X; Wang X; Xu X; Bai L; Xie J; Yao Z; Yi Q; Ma J; Wang J; Zhuo J; Hu C
    Neuropsychiatr Dis Treat; 2018; 14():2087-2097. PubMed ID: 30147321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
    Polosan M; Rabbani M; Christensen MC; Simonsen K; Ren H
    Neuropsychiatr Dis Treat; 2022; 18():1963-1974. PubMed ID: 36068858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
    Mattingly GW; Ren H; Christensen MC; Katzman MA; Polosan M; Simonsen K; Hammer-Helmich L
    Front Psychiatry; 2022; 13():824831. PubMed ID: 35356713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China.
    Chen H; Lin Q; Lin T; Lin Y; Lin X; Chen R; Luo L; Lin F; Xiao Y
    J Psychiatr Res; 2019 Jul; 114():133-140. PubMed ID: 31075722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical observation on treatment of major depressive disorder by paroxetine combined with chaihu xiaoyao mixture].
    Yi ZH; Zhu LP; Long B
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Dec; 30(12):1257-60. PubMed ID: 21302485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of Guipi decoction combined with escitalopram oxalate tablets in patients with depression.
    Yu J; Xu FQ
    World J Clin Cases; 2023 Oct; 11(29):7017-7025. PubMed ID: 37946779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study.
    McCue M; Sarkey S; Eramo A; François C; Parikh SV
    BMC Psychiatry; 2021 Dec; 21(1):622. PubMed ID: 34895181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.
    Cao B; Park C; Subramaniapillai M; Lee Y; Iacobucci M; Mansur RB; Zuckerman H; Phan L; McIntyre RS
    Front Psychiatry; 2019; 10():17. PubMed ID: 30766492
    [No Abstract]   [Full Text] [Related]  

  • 18. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Korean Version of the Perceived Deficits Questionnaire-Depression for Patients with Major Depressive Disorder.
    Kim JM; Hong JP; Kim SD; Kang HJ; Lee YS
    Clin Psychopharmacol Neurosci; 2016 Feb; 14(1):26-32. PubMed ID: 26792037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability and Validity of THINC-it in Evaluating Cognitive Function of Patients with Bipolar Depression.
    Zhang W; Zhu N; Lai J; Liu J; Ng CH; Chen J; Qian C; Du Y; Hu C; Chen J; Hu J; Wang Z; Zhou H; Xu Y; Fang Y; Shi C; Hu S
    Neuropsychiatr Dis Treat; 2020; 16():2419-2428. PubMed ID: 33116541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.